{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:07:25Z","timestamp":1786993645977,"version":"build-2736575974"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100007928","name":"Ningbo Municipal Bureau of Science and Technology","doi-asserted-by":"publisher","award":["202002N3174"],"award-info":[{"award-number":["202002N3174"]}],"id":[{"id":"10.13039\/501100007928","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.leukres.2023.107041","type":"journal-article","created":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T15:59:12Z","timestamp":1676390352000},"page":"107041","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Recombinant human p53 adenovirus injection combined with Bortezomib inhibits proliferation and promotes apoptosis in multiple myeloma"],"prefix":"10.1016","volume":"127","author":[{"given":"Qiangsheng","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiqin","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingchao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijing","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.leukres.2023.107041_bib1","first-page":"575","article-title":"[Multiple myeloma - current status in diagnostic testing and therapy]","volume":"155","author":"Kehrer","year":"2017","journal-title":"Z. Orthop. Unf."},{"issue":"1","key":"10.1016\/j.leukres.2023.107041_bib2","first-page":"43","article-title":"Cancer statistics, 2007","volume":"57","author":"Jemal","year":"2007","journal-title":"CA Cancer J. Clin."},{"issue":"1","key":"10.1016\/j.leukres.2023.107041_bib3","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s40265-017-0841-y","article-title":"Current and new therapeutic strategies for relapsed and refractory multiple myeloma: an update","volume":"78","author":"Nijhof","year":"2018","journal-title":"Drugs"},{"issue":"53","key":"10.1016\/j.leukres.2023.107041_bib4","doi-asserted-by":"crossref","first-page":"7621","DOI":"10.1038\/sj.onc.1203285","article-title":"Twenty years of p53 research: structural and functional aspects of the p53 protein","volume":"18","author":"May","year":"1999","journal-title":"Oncogene"},{"issue":"9","key":"10.1016\/j.leukres.2023.107041_bib5","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1038\/sj.onc.1210263","article-title":"Coping with stress: multiple ways to activate p53","volume":"26","author":"Horn","year":"2007","journal-title":"Oncogene"},{"issue":"7433","key":"10.1016\/j.leukres.2023.107041_bib6","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/nature11743","article-title":"Serine starvation induces stress and p53-dependent metabolic remodelling in cancer cells","volume":"493","author":"Maddocks","year":"2013","journal-title":"Nature"},{"issue":"23","key":"10.1016\/j.leukres.2023.107041_bib7","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21239026","article-title":"Targeting casein kinase 1 (CK1) in hematological cancers","volume":"21","author":"Janovsk\u00e1","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.leukres.2023.107041_bib8","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.blre.2017.03.001","article-title":"p53 dysregulation in B-cell malignancies: more than a single gene in the pathway to hell","volume":"31","author":"Tessoulin","year":"2017","journal-title":"Blood Rev."},{"issue":"11","key":"10.1016\/j.leukres.2023.107041_bib9","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1158\/1535-7163.MCT-10-0471","article-title":"RITA inhibits multiple myeloma cell growth through induction of p53-mediated caspase-dependent apoptosis and synergistically enhances nutlin-induced cytotoxic responses","volume":"9","author":"Saha","year":"2010","journal-title":"Mol. Cancer Ther."},{"issue":"5","key":"10.1016\/j.leukres.2023.107041_bib10","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1001\/jama.2022.0003","article-title":"Diagnosis and management of multiple myeloma: a review","volume":"327","author":"Cowan","year":"2022","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.leukres.2023.107041_bib11","doi-asserted-by":"crossref","DOI":"10.1111\/sji.12910","article-title":"Overview of anti-BCMA CAR-T immunotherapy for multiple myeloma and relapsed\/refractory multiple myeloma","volume":"92","author":"Feng","year":"2020","journal-title":"Scand. J. Immunol."},{"issue":"9","key":"10.1016\/j.leukres.2023.107041_bib12","first-page":"762","article-title":"[The efficacy and safety of PAD and VAD regimens for untreated multiple myeloma]","volume":"49","author":"Zhao","year":"2010","journal-title":"Zhonghua Nei Ke Za Zhi"},{"key":"10.1016\/j.leukres.2023.107041_bib13","doi-asserted-by":"crossref","DOI":"10.1007\/s11523-022-00897-8","article-title":"What's old is new: the past, present and future role of thalidomide in the modern-day management of multiple myeloma","author":"Costa","year":"2022","journal-title":"Target Oncol."},{"issue":"6810","key":"10.1016\/j.leukres.2023.107041_bib14","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/35042675","article-title":"Surfing the p53 network","volume":"408","author":"Vogelstein","year":"2000","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.leukres.2023.107041_bib15","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1038\/nrc864","article-title":"Live or let die: the cell's response to p53","volume":"2","author":"Vousden","year":"2002","journal-title":"Nat. Rev. Cancer"},{"issue":"6","key":"10.1016\/j.leukres.2023.107041_bib16","doi-asserted-by":"crossref","first-page":"667","DOI":"10.2174\/138945010791170833","article-title":"Targeting the p53-family in cancer and chemosensitivity: triple threat","volume":"11","author":"Chung","year":"2010","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.leukres.2023.107041_bib17","doi-asserted-by":"crossref","first-page":"209","DOI":"10.4137\/CMO.S8014","article-title":"Current and emerging treatment options for patients with relapsed myeloma","volume":"7","author":"Castelli","year":"2013","journal-title":"Clin. Med. Insights Oncol."},{"issue":"5","key":"10.1016\/j.leukres.2023.107041_bib18","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1182\/blood-2006-03-009910","article-title":"Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation","volume":"108","author":"Hanamura","year":"2006","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.leukres.2023.107041_bib19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0030215","article-title":"Targeting p53 via JNK pathway: a novel role of RITA for apoptotic signaling in multiple myeloma","volume":"7","author":"Saha","year":"2012","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.leukres.2023.107041_bib20","doi-asserted-by":"crossref","first-page":"a001222","DOI":"10.1101\/cshperspect.a001222","article-title":"p53-based cancer therapy","volume":"2","author":"Lane","year":"2010","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.leukres.2023.107041_bib21","doi-asserted-by":"crossref","DOI":"10.1017\/S1462399408000744","article-title":"P21 and p27: roles in carcinogenesis and drug resistance","volume":"10","author":"Abukhdeir","year":"2008","journal-title":"Expert Rev. Mol. Med."},{"issue":"1","key":"10.1016\/j.leukres.2023.107041_bib22","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1186\/s12943-018-0916-8","article-title":"LncRNA MIR31HG targets HIF1A and P21 to facilitate head and neck cancer cell proliferation and tumorigenesis by promoting cell-cycle progression","volume":"17","author":"Wang","year":"2018","journal-title":"Mol. Cancer"},{"issue":"2","key":"10.1016\/j.leukres.2023.107041_bib23","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41571-020-00450-4","article-title":"Translating noninvasive molecular responses into clinical reality for cancer immunotherapy","volume":"18","author":"Murray","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.leukres.2023.107041_bib24","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/S0301-472X(01)00677-4","article-title":"Additive effect of Apo2L\/TRAIL and Adeno-p53 in the induction of apoptosis in myeloma cell lines","volume":"29","author":"Liu","year":"2001","journal-title":"Exp. Hematol."},{"issue":"3","key":"10.1016\/j.leukres.2023.107041_bib25","doi-asserted-by":"crossref","first-page":"277","DOI":"10.4161\/cc.7.3.5328","article-title":"Protective mechanisms of p53-p21-pRb proteins against DNA damage-induced cell death","volume":"7","author":"Garner","year":"2008","journal-title":"Cell Cycle"},{"issue":"4","key":"10.1016\/j.leukres.2023.107041_bib26","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1159\/000479407","article-title":"Cyclin-dependent kinase inhibitor p21WAF1\/CIP1 facilitates the development of cardiac hypertrophy","volume":"42","author":"Tong","year":"2017","journal-title":"Cell Physiol. Biochem."},{"key":"10.1016\/j.leukres.2023.107041_bib27","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.3389\/fonc.2019.01325","article-title":"Novel breast-specific long non-coding RNA LINC00993 acts as a tumor suppressor in triple-negative breast cancer","volume":"9","author":"Guo","year":"2019","journal-title":"Front. Oncol."},{"issue":"6","key":"10.1016\/j.leukres.2023.107041_bib28","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/nrc2657","article-title":"p21 in cancer: intricate networks and multiple activities","volume":"9","author":"Abbas","year":"2009","journal-title":"Nat. Rev. Cancer"},{"issue":"10","key":"10.1016\/j.leukres.2023.107041_bib29","doi-asserted-by":"crossref","first-page":"4105","DOI":"10.1182\/blood-2002-10-3067","article-title":"Potentiation of dexamethasone-, paclitaxel-, and Ad-p53-induced apoptosis by Bcl-2 antisense oligodeoxynucleotides in drug-resistant multiple myeloma cells","volume":"101","author":"Liu","year":"2003","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.leukres.2023.107041_bib30","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.3892\/ijo.2016.3760","article-title":"FOXO3a orchestrates glioma cell responses to starvation conditions and promotes hypoxia-induced cell death","volume":"49","author":"Brucker","year":"2016","journal-title":"Int. J. Oncol."},{"issue":"4","key":"10.1016\/j.leukres.2023.107041_bib31","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1093\/nar\/gkr934","article-title":"Upregulation of Cyclin B1 by miRNA and its implications in cancer","volume":"40","author":"Huang","year":"2012","journal-title":"Nucleic Acids Res."},{"issue":"2","key":"10.1016\/j.leukres.2023.107041_bib32","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1093\/carcin\/bgm269","article-title":"Overexpression of cyclin B1 in human esophageal squamous cell carcinoma cells induces tumor cell invasive growth and metastasis","volume":"29","author":"Song","year":"2008","journal-title":"Carcinogenesis"},{"issue":"5","key":"10.1016\/j.leukres.2023.107041_bib33","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.ccr.2013.03.013","article-title":"Restoring p53 function in human melanoma cells by inhibiting MDM2 and cyclin B1\/CDK1-phosphorylated nuclear iASPP","volume":"23","author":"Lu","year":"2013","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.leukres.2023.107041_bib34","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.mehy.2014.06.013","article-title":"CCNB1 is a prognostic biomarker for ER+ breast cancer","volume":"83","author":"Ding","year":"2014","journal-title":"Med. Hypotheses"},{"issue":"4\u20135","key":"10.1016\/j.leukres.2023.107041_bib35","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.jsbmb.2009.10.005","article-title":"Clinical, pathological, proliferative and molecular responses associated with neoadjuvant aromatase inhibitor treatment in breast cancer","volume":"118","author":"Miller","year":"2010","journal-title":"J. Steroid Biochem. Mol. Biol."},{"issue":"1","key":"10.1016\/j.leukres.2023.107041_bib36","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/nyas.12986","article-title":"Regulation of hematopoietic stem cell integrity through p53 and its related factors","volume":"1370","author":"Yamashita","year":"2016","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"9","key":"10.1016\/j.leukres.2023.107041_bib37","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1002\/jcp.22561","article-title":"The p53 tumor suppressor protein regulates hematopoietic stem cell fate","volume":"226","author":"Asai","year":"2011","journal-title":"J. Cell Physiol."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212623000267?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212623000267?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T01:03:24Z","timestamp":1758935004000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212623000267"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":37,"alternative-id":["S0145212623000267"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2023.107041","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recombinant human p53 adenovirus injection combined with Bortezomib inhibits proliferation and promotes apoptosis in multiple myeloma","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2023.107041","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107041"}}